Why is Faeth Therapeutics stock surging today?

Faeth Therapeutics (FTH) stock rose 10.1% in pre-market trading after presenting Phase II endometrial cancer data at the Jefferies Global Healthcare Conference, showing a 33% overall response rate. The company also announced a clinical partnership with Roche. H.C. Wainwright reiterated its Buy rating and $60 price target, citing a 55% stock decline since November 9 as disconnected from clinical progress.

Original reporting
Published Nov 18, 2026, 12:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 12:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$FTH
Bullish
high confidence
Mentioned
$FTH
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$FTHBullishMed
01

Why it matters

The article links the pre-open surge to newly presented Phase II endometrial cancer results and a newly formed Roche partnership that expands PIKTOR into a breast cancer combination study while preserving rights.

02

Market read

Same-day catalyst is a conference presentation with specific Phase II efficacy metrics and a Roche-backed clinical expansion, driving momentum in a clinical-stage biotech.

03

What to watch

The article does not specify trial size details beyond 36 patients or timing to next readouts, so the market may be front-running future data and regulatory/financing needs.

Relevance 7/10Novelty 6/10Timing: pre-market today after pre-open surge

Background

Faeth Therapeutics (FTH) is a clinical-stage oncology biotech with lead program PIKTOR, and the stock had been near multi-month lows before this conference-driven attention.

Company-level read

Ticker impact

$FTHBullishHigh confidence
Context

Faeth Therapeutics shares surged pre-open after Phase II endometrial cancer data for PIKTOR and a new Roche clinical partnership were highlighted at the Jefferies conference.

Expected impact

Likely upward pressure as traders price in improved PIKTOR differentiation and the validation signal from Roche.

Evidence & confidence

The article attributes the same-day pre-market rally to specific Phase II efficacy numbers and a newly formed Roche partnership, both direct catalysts for sentiment and valuation expectations.

Market effects

Reinforces positive read-through for clinical-stage oncology biotech sentiment when conference readouts and pharma partnerships hit.

Primarily US pre-market momentum, with broader index gains providing supportive liquidity conditions.

London conference data and Roche partnership add international validation, but the trading catalyst is US-listed equity flow.

Counterpoint

Conference presentations can overstate durability; traders may fade the move if follow-up filings or endpoints do not confirm the headline response rates.

Key entities

  • Faeth Therapeutics

    Subject of the article, with shares surging pre-open on new PIKTOR Phase II data and a Roche partnership.

  • PIKTOR

    Faeth’s lead oncology program; Phase II endometrial cancer data and combination study plans are cited.

  • Roche

    Partner in a newly formed clinical collaboration and supply agreement involving PIKTOR and giredestrant.

  • Jefferies Global Healthcare Conference

    Venue where the prior evening presentation reportedly renewed investor attention.

  • H.C. Wainwright

    Reiterated Buy rating and $60 price target, cited as reinforcing the move.

Related articles

$FTHMed

Faeth Therapeutics stock gets $60 target on Roche collaboration

Faeth Therapeutics (FTH) received a $60 price target from H.C. Wainwright after announcing a clinical trial collaboration with Roche to evaluate PIKTOR in combination with giredestrant for advanced breast cancer. The stock has fallen 55% since November 9, trading at $9.28. Analysts cite undervaluation and positive Phase 2 trial results for PIKTOR in endometrial cancer, with a 33% response rate.

$FTHMedAI 8/10

Baird reiterates Faeth Therapeutics stock rating on PIK-201 data

Baird reiterated an Outperform rating on Faeth Therapeutics (FTH) with a $57 price target, citing positive PIK-201 data. The stock is down 35% in a week, trading at $12.79. Analysts highlight its potential in endometrial and breast cancer, with a market cap of $333M and strong financial metrics. Recent clinical trials showed a 33% response rate in endometrial cancer.

$FTHHighAI 8/10

Faeth Therapeutics stock rating reiterated at Buy by H.C. Wainwright

H.C. Wainwright reiterated a Buy rating and $60 price target for Faeth Therapeutics (FTH) after positive Phase 2 trial results for PIKTOR. The trial showed a 33% objective response rate and 7.4-month median progression-free survival, outperforming typical chemotherapy benchmarks. Despite a 45% stock decline, analysts highlight the drug's potential and manageable toxicity. Other firms also reiterated positive ratings, and the company appointed a new board member.